An Open Label Study of Oral Enzastaurin in Participants With Cancer
An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies
Sponsor: Eli Lilly and Company
Listed as NCT00309140, this PHASE2 trial focuses on Cancer and Neoplasms and remains completed. Sponsored by Eli Lilly and Company, it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .